Biogen Idec, Inc. (BIIB) Tops Q4 EPS by 2c; Guides FY12 EPS Below View
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $198.91 --0%
EPS Growth %: -41.5%
Financial Fact:
Net income attributable to Biogen Idec Inc.: 1.03B
Today's EPS Names:
CCEL, FEIM, PLG, More
EPS Growth %: -41.5%
Financial Fact:
Net income attributable to Biogen Idec Inc.: 1.03B
Today's EPS Names:
CCEL, FEIM, PLG, More
Join SI Premium – FREE
Biogen Idec, Inc. (NASDAQ: BIIB) reported Q4 EPS of $1.51, $0.02 better than the analyst estimate of $1.49. Revenue for the quarter came in at $1.3 billion versus the consensus estimate of $1.29 billion.
Biogen Idec, Inc. sees FY2012 EPS of $6.10-$6.20, versus the consensus of $6.32.
For earnings history and earnings-related data on Biogen Idec, Inc. (BIIB) click here.
Biogen Idec, Inc. sees FY2012 EPS of $6.10-$6.20, versus the consensus of $6.32.
For earnings history and earnings-related data on Biogen Idec, Inc. (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Fiserv (FISV) PT Lowered to $62 at Baird, 'designating as a bearish Fresh Pick into earnings'
- Intel (INTC) Price Target Raised to $120 by Stifel Ahead on Expected Earnings Beat
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
